Leerink analyst Whit Mayo lowered the firm’s price target on Ardent Health (ARDT) to $16 from $23 and keeps an Outperform rating on the shares following Q3 results. The firm believes the equity reaction seems overly harsh compared to the guide down. However, Leerink can see a probable scenario that there is entirely no growth next year, the firm told investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health price target lowered to $16 from $21 at RBC Capital
- Ardent Health price target lowered to $17 from $19 at Loop Capital
- Ardent Health price target lowered to $13 from $21 at Truist
- Ardent Health price target lowered to $12 from $19 at Goldman Sachs
- Ardent Health price target lowered to $17 from $21 at Stephens